TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04573361

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chiropractic care (one visit)
Description: One visit to the chiropractor based on the use of spinal manipulative therapy, mobilization and other forms of manual therapy, exercise therapy, patient education, advice and reassurance

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chiropractic care (more than one visit)
Description: More than one visit to the chiropractor based on the use of spinal manipulative therapy, mobilization and other forms of manual therapy, exercise therapy, patient education, advice and reassurance
Study: NCT03095482

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Participants will receive 20 minutes of either active or sham tDCS prior to in vivo exposure to feared targets.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In vivo exposure therapy
Description: Participants will receive 30 minutes of in vivo exposure to feared targets following either active or sham tDCS
Study: NCT04247113

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-based prevention following bariatric surgery
Description: PBP-B is an adapted version of Parent-Based Prevention (PBP), an innovative approach with demonstrated efficacy in targeting the familial effects of parents with eating disorders on their young children's healthy behaviors. PBP-B addresses the parental cognitions and behaviors that putatively increase the risk for maladaptive outcomes in their children.
Study: NCT00733421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoricoxib
Description: 90 mg once daily
Study: NCT03095482

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: In vivo exposure therapy
Description: Participants will receive 30 minutes of in vivo exposure to feared targets following either active or sham tDCS
Study: NCT01253889

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose 25% oral solution
Description: 0.5ml of 25% glucose (26-31 weeks gestational age group) or 1.0 ml of 25% glucose (32-42 weeks gestational age group). This application can be repeated if necessary to a maximum of four times, adding up to max 2ml of 25% glucose in the 26-31 weeks gestational age group or 4ml of 25% glucose in the 32-42 weeks gestational age group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose 25% oral solution
Description: 0.5ml of 25% glucose (26-31 weeks gestational age group) or 1.0 ml of 25% glucose (32-42 weeks gestational age group). This application can be repeated if necessary to a maximum of four times, adding up to max 2ml of 25% glucose in the 26-31 weeks gestational age group or 4ml of 25% glucose in the 32-42 weeks gestational age group.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oral water
Description: 0.5ml of oral water (26-31 weeks gestational age group) or 1.0 ml of oral water (32-42 weeks gestational age group). This application can be repeated if necessary to a maximum of four times, adding up to max 2ml of oral water in the 26-31 weeks gestational age group or 4ml of oral water in the 32-42 weeks gestational age group.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oral water
Description: 0.5ml of oral water (26-31 weeks gestational age group) or 1.0 ml of oral water (32-42 weeks gestational age group). This application can be repeated if necessary to a maximum of four times, adding up to max 2ml of oral water in the 26-31 weeks gestational age group or 4ml of oral water in the 32-42 weeks gestational age group.
Study: NCT02501031

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ground flaxseed
Description: 2 tablespoons of ground flaxseed taken daily for approximately 50 days.
Study: NCT02245360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phleum pratense grass pollen allergen extract
Description: Allergy Immunotherapy grass tablet 75,000 SQ-T given once daily over 60 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablet given once daily over 60 days
Study: NCT03179501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP001
Description: NP001

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study: NCT00918229

Intervention type: DEVICE
Group type: OTHER
Intervention: balloon implant
Description: Absorbable perirectal spacer implantation

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Balloon implantation
Description: Implantation of the balloon between the prostate and the anterior rectal wall
Study: NCT03582007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Murepavadin
Description: Murepavadin + ertapenem

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: One anti-pseudomonal antibiotic
Description: Either meropenem or piperacillin-tazobactam
Study: NCT02841605

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Rectosigmoidoscopy with colonic biopsies
Description: Rectosigmoidoscopy with colonic biopsies performed for Alzheimer patient and both control groups Parkinson and PSP

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Rectosigmoidoscopy with colonic biopsies
Description: Rectosigmoidoscopy with colonic biopsies performed for Alzheimer patient and both control groups Parkinson and PSP

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Rectosigmoidoscopy with colonic biopsies
Description: Rectosigmoidoscopy with colonic biopsies performed for Alzheimer patient and both control groups Parkinson and PSP

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Colonoscopy with colonic biopsies
Description: Colonoscopy with colonic biopsies performed only in patient at risk of colic cancer
Study: NCT05043727

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Exer gaming
Description: exer gaming treatment plan will include perfect ten balance, wii skiing, wiicycling. Each Patient will receive twenty four sessions. Each treatment session was of 50 minutes with two minutes rest between each exercise.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment plan
Description: it will receive conventional treatment plan which includes balance training, gait training, stretching and strengthening exercises.Each patient will receive twenty four sessions of conventional physical therapy. Treatment session will be of 50 minutes with 2 minutes rest period between each exercise.
Study: NCT03978169

Intervention type: DIAGNOSTIC_TEST
Intervention: pleuropulmonary ultrasound
Description: three pleuro-pulmonary ultrasound scans will be performed, preoperatively on the day of surgery, post-operatively in the recovery room and the day after surgery

Intervention type: DIAGNOSTIC_TEST
Intervention: pleuropulmonary ultrasound
Description: three pleuro-pulmonary ultrasound scans will be performed, preoperatively on the day of surgery, post-operatively in the recovery room and the day after surgery

Intervention type: DIAGNOSTIC_TEST
Intervention: pleuropulmonary ultrasound
Description: three pleuro-pulmonary ultrasound scans will be performed, preoperatively on the day of surgery, post-operatively in the recovery room and the day after surgery
Study: NCT00973856

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PURELL VF481
Description: One (1) pump of test product (approximately 1.5ml) is applied to a wooden applicator and gently rubbed into the wart, then covered with a latex free adhesive bandage (it is not necessary to wait until dry) each night before bed

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PURELL VF481
Description: One (1) pump of test product (approximately 1.5ml) is applied to a wooden applicator and gently rubbed into the wart, then covered with a latex free adhesive bandage (it is not necessary to wait until dry) each night before bed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Solution
Description: One (1) pump of product (approximately 1.5ml) is applied to a wooden applicator and gently rubbed into the wart, then covered with a latex free adhesive bandage (it is not necessary to wait until dry) each night before bed

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Solution
Description: One (1) pump of product (approximately 1.5ml) is applied to a wooden applicator and gently rubbed into the wart, then covered with a latex free adhesive bandage (it is not necessary to wait until dry) each night before bed
Study: NCT03060031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin intranasal administration, 40 IU, 5 puffs per nostril at 4 IU per puff delivered approximately 45 minutes prior to pain tasks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intranasal administration, 5 puffs per nostril delivered approximately 45 minutes prior to pain tasks
Study: NCT02726217

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CareSmarts Mobile Health Diabetes Program
Description: Nurses from Diabetes Clinic will use a web-based enrollment form that includes the patient's mobile phone number, diabetes care plan, and preferred times for receiving messages. Participants in the program receive text messages about diabetes self-care. The contents of the messages that the participants receive are modified through software every two weeks as needed, based on their interactions with the system. Participants follow a flexible education curriculum in which they move from one topic to the next at their own pace.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care Reminders and Self Assessments

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Reminders and Self Assessments
Study: NCT00944437

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Helmet
Description: Continuous positive airway pressure for up to 24 h. Initial pressure will be 5 cmH2O, and will be increased by 2-3 cmH2O up to 10 cmH2O, in order to maintain SpO2 ≥90%.
Study: NCT04107090

Intervention type: OTHER
Group type: OTHER
Intervention: lung recruitment maneuver
Description: Lung recruitment maneuver done for ventilated preterm neonates diagnosed with respiratory distress syndrome

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lung recruitment maneuver
Description: Lung recruitment maneuver done for ventilated preterm neonates diagnosed with respiratory distress syndrome

Intervention type: OTHER
Group type: OTHER
Intervention: tracheal IL-6 level
Description: tracheal IL-6 level was measured before and after recruitment maneuver

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tracheal IL-6 level
Description: tracheal IL-6 level was measured before and after recruitment maneuver

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: US guided lung recruitment maneuver
Description: Lung recruitment maneuver done for ventilated preterm neonates diagnosed with respiratory distress syndrome guided by lung ultrasound
Study: NCT00147966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: treatment with rituximab
Study: NCT00944437

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Full-face mask
Description: Continuous positive airway pressure for up to 24 h. Initial pressure will be 5 cmH2O, and will be increased by 2-3 cmH2O up to 10 cmH2O, in order to maintain SpO2 ≥90%.
Study: NCT02790385

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Gauze Treatment
Study: NCT01806337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Consolidation after CHOP induction
Study: NCT02888405

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Study: NCT04039516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutathera
Description: A total of 4 infusions of Lutathera to be administered every 8 weeks.
Study: NCT00987298

Intervention type: DEVICE
Intervention: Visceral fat mass measurement
Description: Total body DXA measurement, Abdominal CT scan
Study: NCT04679220

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preheating
Description: For preheating RC prior to placement, a device called Therma-flo TM RC warming kit (Vista, Wisconsin, USA) was used according to manufacturer's instructions to preheat resin composites

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Preheating
Description: For preheating RC prior to placement, a device called Therma-flo TM RC warming kit (Vista, Wisconsin, USA) was used according to manufacturer's instructions to preheat resin composites
Study: NCT01165281

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone CR
Description: One 5 mg to 40 mg capsule twice daily for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R331333 (referred to as JNS024 ER or CG5503)
Description: One 25 mg to 200 mg capsule twice daily for 4 weeks.
Study: NCT05450874

Intervention type: PROCEDURE
Intervention: hepatectomy

Intervention type: PROCEDURE
Intervention: hepatectomy
Study: NCT00364858

Intervention type: DRUG
Group type: OTHER
Intervention: Cerezyme
Description: Cerezyme doses of 20-60U/kg every 2 weeks (Q2 Arm) or 40-120 U/kg every 4 weeks (Q4 Arm).

Intervention type: DRUG
Group type: OTHER
Intervention: Cerezyme
Description: Cerezyme doses of 20-60U/kg every 2 weeks (Q2 Arm) or 40-120 U/kg every 4 weeks (Q4 Arm).
Study: NCT00326378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: consolidation chemotherapy with Docetaxel plus cisplatin
Description: definitive CCRT, and followed by consolidation chemotherapy with three cycles of docetaxel plus cisplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CCRT arm without consolidation chemotherapy
Description: definitive CCRT with weekly Docetaxel/CDDP #6 without consolidation chemotherapy
Study: NCT01468402

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Image
Description: The leiomyomas were evaluated individually. MR was used to evaluate morphology: the radiological dimension(s) of the leiomyoma and uterus and the volume. The number of leiomyoma fibroids was determined, and their location in the myometrium. Perfusion and the characterization of the T2 signal were also evaluated.
Study: NCT00581529

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: Patients on protocol will be treated with accelerated radiotherapy, 3.85 Gy per fraction, bid, for 5 consecutive days for a total dose of 38.5 Gy.
Study: NCT04936022

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric Exercise
Description: Prescribed 6 months of isometric exercise training (three sessions per week, comprised of 4 x 2-minute bouts with 2-minute recovery periods in-between).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard care lifestyle advice
Description: Healthy lifestyle advice for hypertension, given by a healthcare professional.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard care lifestyle advice
Description: Healthy lifestyle advice for hypertension, given by a healthcare professional.
Study: NCT01274546

Intervention type: DEVICE
Intervention: cruciate-retaining Foundation Knee system
Description: subjects who received the cruciate-retaining Foundation Knee system greater than or equal to 10 years ago and still maintain the original device in their knee.

Intervention type: DEVICE
Intervention: cruciate-retaining Foundation Knee system
Description: subjects who received the cruciate-retaining Foundation Knee system greater than or equal to 10 years ago and still maintain the original device in their knee.
Study: NCT03387852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR440340
Description: Pharmaceutical form: Solution for Injection, Route of administration: SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR440340
Description: Pharmaceutical form: Solution for Injection, Route of administration: SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dupilumab
Description: Pharmaceutical form: Solution for Injection, Route of administration: SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Pharmaceutical form: Solution for Injection, Route of administration: SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone or Fluticasone/salmeterol combination
Description: Pharmaceutical form: Aerosol, dry powder, Route of administration: Inhaled
Study: NCT03900286

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Total Dietary Replacement
Description: Total Dietary Replacement
Study: NCT03387852

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone or Fluticasone/salmeterol combination
Description: Pharmaceutical form: Aerosol, dry powder, Route of administration: Inhaled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone or Fluticasone/salmeterol combination
Description: Pharmaceutical form: Aerosol, dry powder, Route of administration: Inhaled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone or Fluticasone/salmeterol combination
Description: Pharmaceutical form: Aerosol, dry powder, Route of administration: Inhaled

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for SAR440340
Description: Pharmaceutical form: Solution for Injection, Route of administration: SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for SAR440340
Description: Pharmaceutical form: Solution for Injection, Route of administration: SC
Study: NCT01774695

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Increased physical activity
Description: The subjects were encouraged to increase their level of physical activity for 12 weeks in the previous study.~The advice was individual but was based on the recommendations of the Swedish National Institute of health. The recommendation for increasing cardiorespiratory fitness is 20-60 minutes of moderate to vigorous intensive physical activity 3 to 5 days per week.
Study: NCT01222715

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine Tartrate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine Tartrate
Description: Given IV
Study: NCT03740685

Intervention type: DIAGNOSTIC_TEST
Intervention: High sesitive C reactive protien
Description: High sesitive C reactive protien will be evaluated at admission time and after 36 hours
Study: NCT02056405

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mosapride
Description: 15 mg per day divided into 3 oral intakes of 5 mg each (1 pill of Mosapride every 8 hs with 30 ml tap water). This treatment will begin on postoperative day 1 until discharge from Hospital or unacceptable toxicity develops.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 pill of the same characteristics as Mosapride every 8 hs with 30 ml tap water. This will begin on postoperative day 1 until discharge from Hospital or unacceptable toxicity develops.
Study: NCT00990119

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vapotherm High Flow Therapy
Description: use of high flow nasal cannula to support oxygenation and CO2 removal by flushing the nasopharynx with warmed, humidified respiratory gas at flow rates that exceed a patient's inspiratory flow rate

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive positive pressure ventilation
Description: Patients will be fit with an oronasal mask using a fitting gauge that will be applied by a respiratory therapist or other clinician skilled in management of NIPPV. Initial pressures will be at low end of suggested range but can be increased as rapidly as necessary to alleviate respiratory distress.
Study: NCT00733421

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tramadol
Description: 100 mg twice daily
Study: NCT02811510

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill (no active cannabinoids)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dronabinol
Description: 10 mg capsule of Dronabinol will be administered orally.
Study: NCT01598272

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitality product AM + Vitality product PM
Description: Vitality AM: Tak 6 capsules daily for 56 days Vitality PM: Take 2 capsules daily for 56 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo AM: Take 6 capsules daily for 56 days Placebo PM: Take 2 capsules daily for 56 days
Study: NCT01760135

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high caloric nutritional supplement
Description: high caloric nutritional supplement (25kcal/kg)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: low caloric nutritional supplement
Description: low caloric nutritional supplement(15kcal/kg)
Study: NCT01805089

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin 3 mg
Description: Melatonin vs. Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Melatonin 3 mg
Description: Melatonin vs. Placebo
Study: NCT00191477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 2000 mg, intravesicular instillation x 1 immediately post transurethral resection of the bladder tumor (TUR-BT)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravesicular instillation x 1 immediately post transurethral resection of the bladder tumor (TUR-BT)
Study: NCT03760107

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connect Smokers to Treatment 1
Description: Using a factorial experimental design, the investigators evaluate how coupling a population-based, direct mail intervention with (1) financial incentives and (2) proactive telephone outreach influences connections to evidence-based tobacco treatment services among low-SES smokers.
Study: NCT01916096

Intervention type: DEVICE
Intervention: Delica Device

Intervention type: DEVICE
Intervention: Delica Device

Intervention type: DEVICE
Intervention: Delica Device

Intervention type: DEVICE
Intervention: Delica Device

Intervention type: DEVICE
Intervention: Delica Device

Intervention type: DEVICE
Intervention: Delica Device
Study: NCT00629252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertindole
Description: oral 12-20 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: oral 2-6mg / day